NCT01552434 - Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease | Biotech Hunter

Enrollment

155

Participants

Timeline

Start Date

March 16, 2012

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions

Advanced Malignant NeoplasmCastleman DiseaseDigestive System CarcinomaErdheim-Chester DiseaseLip and Oral Cavity CarcinomaLymphangioleiomyomatosisMalignant Endocrine NeoplasmMalignant Female Reproductive System NeoplasmMalignant Male Reproductive System NeoplasmMalignant NeoplasmMalignant Respiratory Tract NeoplasmMalignant Thoracic NeoplasmMalignant Urinary System NeoplasmMesothelial NeoplasmMetastatic Malignant NeoplasmMetastatic Urothelial CarcinomaNeurofibromatosis Type 2Recurrent Adult Soft Tissue SarcomaRecurrent Breast CarcinomaRecurrent Childhood Soft Tissue SarcomaRecurrent Digestive System CarcinomaRecurrent Female Reproductive System CarcinomaRecurrent Male Reproductive System CarcinomaRecurrent Malignant NeoplasmRecurrent Pharyngeal CarcinomaRecurrent Thyroid Gland CarcinomaRefractory Malignant NeoplasmSoft Tissue NeoplasmStage III Breast Cancer AJCC v7Stage III Pharyngeal CancerStage IIIA Breast Cancer AJCC v7Stage IIIB Breast Cancer AJCC v7Stage IIIC Breast Cancer AJCC v7Stage IV Breast Cancer AJCC v6 and v7Stage IV Pharyngeal CancerStage IVA Pharyngeal CancerStage IVB Pharyngeal CancerStage IVC Pharyngeal CancerThyroid Gland Neoplasm

Interventions

BIOLOGICAL

Bevacizumab

Given IV

BIOLOGICAL

Cetuximab

Given IV

OTHER

Laboratory Biomarker Analysis

Optional correlative studies

OTHER

Pharmacological Study

Optional correlative studies

DRUG

Temsirolimus

Given IV

DRUG

Valproic Acid

Given PO

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER